1. Home
  2. RVSB vs RLYB Comparison

RVSB vs RLYB Comparison

Compare RVSB & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Riverview Bancorp Inc

RVSB

Riverview Bancorp Inc

HOLD

Current Price

$5.28

Market Cap

106.9M

Sector

Finance

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$16.90

Market Cap

89.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSB
RLYB
Founded
1923
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.9M
89.2M
IPO Year
1997
2021

Fundamental Metrics

Financial Performance
Metric
RVSB
RLYB
Price
$5.28
$16.90
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
50.7K
12.2K
Earning Date
04-28-2026
05-11-2026
Dividend Yield
1.55%
N/A
EPS Growth
N/A
N/A
EPS
0.08
6.16
Revenue
N/A
$858,000.00
Revenue This Year
$53.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$66.50
$2.75
Revenue Growth
N/A
43.00
52 Week Low
$4.81
$0.48
52 Week High
$6.22
$17.57

Technical Indicators

Market Signals
Indicator
RVSB
RLYB
Relative Strength Index (RSI) 49.39 57.65
Support Level $5.01 $16.51
Resistance Level $5.56 $17.34
Average True Range (ATR) 0.10 0.45
MACD 0.01 -0.02
Stochastic Oscillator 75.93 50.00

Price Performance

Historical Comparison
RVSB
RLYB

About RVSB Riverview Bancorp Inc

Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment services. It has single operating segment.

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: